

We Claim:

1. A vaccine comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle.
2. A vaccine according to claim 1, wherein the nucleotide sequence is selected from SEQ ID No. 15 or SEQ ID No. 19.
3. A vaccine according to claim 1, wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No. 19.
4. A vaccine according to claim 1, wherein the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof.
5. A vaccine according to claim 4, wherein the homologue has at least 80% sequence identity to SEQ ID No. 23 or SEQ ID No. 25.
6. A vaccine according to claim 4, wherein the nucleotide sequence is SEQ ID No. 25.
7. A vaccine comprising a polypeptide encoded by a nucleotide sequence of the genome of PCVB, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle.
8. A vaccine according to claim 7, wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No. 19.

9. A vaccine according to claim 7, wherein the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof.
10. A vaccine according to claim 9, wherein the homologue has at least 80% sequence identity to SEQ ID No. 23 or SEQ ID No. 25.
11. A vaccine according to claim 9, wherein the nucleotide sequence is SEQ ID No. 25.
12. A vaccine according to claim 7, wherein the polypeptide has the amino acid sequence of SEQ ID No. 24 or SEQ ID No. 26.
13. A vaccine according to claim 12, wherein the polypeptide has the amino acid sequence of SEQ ID No. 26.
14. A vaccine according to claim 7, wherein the homologue has at least 80% sequence identity to SEQ ID No. 24 or SEQ ID No. 26.
15. A vaccine according to claim 14, wherein the homologue has at least 80% sequence identity to SEQ ID No. 26.
16. A vaccine according to claim 7, wherein the polypeptide has the amino acid sequence of SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No. 32.
17. A vaccine comprising a vector and an acceptable pharmaceutical or veterinary vehicle, the vector comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.

18. A vaccine according to claim 17, further comprising a gene coding for an expression product capable of inhibiting or retarding the establishment or development of a genetic or acquired disease.

19. A vaccine comprising a cell and an acceptable pharmaceutical or veterinary vehicle, wherein the cell is transformed with a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.

*Sub 95*  
~~20. A vaccine according to claim 1, further comprising an adjuvant.~~

21. A vaccine comprising a pharmaceutically acceptable vehicle and a single polypeptide, wherein the single polypeptide consists of SEQ ID No. 26.

*Sub 95*  
~~22. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of any one of claims 1-21.~~